CTLA4 and endocrine system disorder: There was no significant difference in other ICI-associated endocrinopathies between patients on anti-CTLA-4 therapy and those on the combination therapy of anti-PD-1 + anti-CTLA-4 (χ2 = 1.064, p = 0.302).